Top Industry Leaders in the Hepatitis B Treatment Market
Brii Bio Their novel drug BRII-179 (VBI-2601) demonstrated encouraging results in Phase 2 trials for achieving a functional cure for Hepatitis B (HBV), meaning undetectable HBV surface antigen and viral DNA after stopping therapy. Phase 3 trials are ongoing.
Gilead Sciences Conducting a Phase 2 trial exploring a combination of their drugs Tenofovir Alafenamide (TAF) and VIR-2218 with other novel therapies for potential functional cure. Results expected in early 2024.
Madrigal Therapeutics Their drug Resmetirom received a New Drug Application (NDA) acceptance from the US FDA for treatment of chronic hepatitis B, with a decision expected by mid-March 2024. This could be a major milestone for the market.
Janssen's exit Unfortunately, the pharmaceutical giant announced its departure from the Hepatitis B treatment market in February 2023, raising concerns about access and innovation.
List of Hepatitis B Treatment Key companies in the market- Accord Healthcare Inc.
- Apotex Corp.
- Arbutus Biopharma
- Arrowhead Pharma
- Aurobindo Pharma Limited
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline
- Lupin Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Par Pharmaceutical, Inc.
- Teva Pharmaceuticals
- Zydus Pharmaceuticals
